Pitt Shield

Breaking Barriers in Neuro-Oncology: A Scoping Literature Review on Invasive and Non-Invasive Techniques for Blood-Brain Barrier Disruption.

Authors: Pinkiewicz M, Pinkiewicz M, Walecki J, Zaczyński A, Zawadzki M

The blood-brain barrier (BBB) poses a significant challenge to drug delivery for brain tumors, with most chemotherapeutics having limited permeability into non-malignant brain tissue and only restricted access to primary and metastatic brain cancers. Consequently, due to the drug's inability to effectively penetrate the BBB, outcomes following brain chemotherapy continue to be suboptimal. Several methods to open the BBB and obtain higher drug concentrations in tumors have been proposed, with the selection of the optimal method depending on the size of the targeted tumor volume, the chosen therapeutic agent, and individual patient characteristics. Herein, we aim to comprehensively describe osmotic disruption with intra-arterial drug administration, intrathecal/intraventricular administration, laser interstitial thermal therapy, convection-enhanced delivery, and ultrasound methods, including high-intensity focused and low-intensity ultrasound as well as tumor-treating fields. We explain the scientific concept behind each method, preclinical/clinical research, advantages and disadvantages, indications, and potential avenues for improvement. Given that each method has its limitations, it is unlikely that the future of BBB disruption will rely on a single method but rather on a synergistic effect of a combined approach. Disruption of the BBB with osmotic infusion or high-intensity focused ultrasound, followed by the intra-arterial delivery of drugs, is a promising approach. Real-time monitoring of drug delivery will be necessary for optimal results.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To comprehensively describe and evaluate methods for disrupting the blood–brain barrier/blood–tumor barrier to enhance drug delivery to brain tumors.
Animal model / Human subject Not specified in the provided text
Disease model Brain tumors (primary and metastatic)
MRI or image guidance method Not specified in the provided text
Targeted brain region(s) Blood–Brain Barrier (Bbb)
Target coordinates Not provided in the text
Cargo name and characteristics Systemic chemotherapeutic agents — primarily small-molecule cytotoxic drugs with intrinsically poor blood–brain barrier penetration; also includes larger therapeutic cargos under investigation for CNS delivery such as monoclonal antibodies and other proteins, viral vectors (AAVs), and engineered nanoparticles, all intended to be delivered or augmented via BBB/BTB disruption methods (intra-arterial osmotic disruption, intrathecal/intraventricular administration, convection-enhanced delivery, and ultrasound- or thermal-facilitated approaches).
Route of administration Intra-arterial administration; intrathecal/intraventricular (CSF) administration; convection-enhanced direct intracerebral/intratumoral delivery; ultrasound-facilitated BBB disruption coupled with intra-arterial delivery

Outcomes and Safety

Summary of Outcomes not report
Duration of biological effect Not reported
Safety-related matter The paper states that osmotic BBB disruption with intra-arterial administration has an acceptable safety profile in experienced hands, and that convection-enhanced delivery allows homogeneous and safe drug delivery but requires further technical refinement and clinical evaluation.

Brain Region

Ultrasound Parameters

Ultrasound instrument Not specified in the provided text.
FUS Frequency Not specified in the provided text
FUS Intensity Not reported in provided text
FUS Mode pulsed
Pulse duration Not specified in the provided text
Duration of a single FUS session Not reported in the provided text
Focal Characteristics Not specified
Treatment frequency multiple sessions

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search